Metabolic syndrome, mild cognitive impairment and dementia

Current Alzheimer Research

Volumn 8, Issue 5, 2011, Pages 492-509

  Panza, F ^a   Frisardi, V ^b   Seripa, D ^a   Imbimbo, B P ^c   Sancarlo, D ^a   D'Onofrio, G ^a   Addante, F ^a   Paris, F ^a   Pilotto, A ^a   Solfrizzi, V ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Alzheimer's disease; Dementia; Diabetes mellitus; HDL cholesterol; Hypertension; Hypertriglyceridemia; Metabolic syndrome; Mild cognitive impairment; Obesity; Predementia syndromes; Vascular dementia; Vascular risk factors

Indexed keywords

C REACTIVE PROTEIN; FATTY ACID; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; BODY MASS; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; KIDNEY DISEASE; LEUKOARAIOSIS; LIPOGENESIS; LIPOLYSIS; METABOLIC SYNDROME X; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; WORD LIST RECALL;

DEMENTIA; HUMANS; METABOLIC SYNDROME X; MILD COGNITIVE IMPAIRMENT; RISK FACTORS;

EID: 79959952090     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511796391818     Document Type: Article

References (212)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus report. Lancet 366: 2112-2117 (2005).
2. Qiu C, de Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 20: 380-385 (2007).
3. Roman GC. Defining dementia: clinical criteria for the diagnosis of vascular dementia. Acta Neurol Scand. Suppl 178: 6-9 (2002).
4. Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 11: 585-590 (2001).
5. Panza F, Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, et al. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 26: 537-555 (2009).
6. Frisardi V, Solfrizzi V, Imbimbo BP, Capurso C, D'Introno A, Colacicco AM, et al. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr Alzheimer Res 7: 40-55 (2010).
7. Panza F, D'Introno A, Colacicco AM, Capurso C, del Parigi A, Caselli RJ, et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry 1: 633-644 (2005).
8. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-308 (1999).
9. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256: 240-246 (2004).
10. Panza F, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Im-bimbo BP, et al. Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am J Geriatr Psychiatry 18: 98-116 (2010).
11. American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; Washington; DC (1994).
12. Levy R. Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatrics 6, 63-68 (1994).
13. Solfrizzi V, Capurso C, D'Introno A, Colacicco AM, Santamato A, Ranieri M, et al. Lifestyle-related factors in predementia and dementia syndromes. Expert Rev Neurother 8: 133-158 (2008).
14. Peters R. The prevention of dementia. Int J Geriatr Psychiatry 24: 452-458 (2009).
15. Hendrie HC, Albert MS, Butters MA, Gao S, Knopman DS, Launer LJ, et al. The NIH Cognitive and Emotional Health Project Report of the Critical Evaluation Study Committee. Alzheimer Dement 2: 12-32 (2006).
16. de la Torre JC. The vascular hypothesis of Alzheimer's disease: bench to bedside and beyond. Neurodegener Dis 7: 116-121 (2010).
17. de la Torre JC, Mussivand T. Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res 15: 146-153 (1993).
18. Skoog I. Vascular aspects in Alzheimer's disease. J Neural Transm Suppl 59: 37-43 (2000)
19. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002: 813-836 (2002).
20. Panza F, D'Introno A, Colacicco AM, Capurso C, Parigi AD, Ca-purso SA, et al. Cognitive frailty: Predementia syndrome and vascular risk factors. Neurobiol Aging 27: 933-940 (2006).
21. Panza F, D'Introno A, Colacicco AM, Basile AM, Capurso C, Kehoe PG, et al. Vascular risk and genetics of sporadic late-onset Alzheimer's disease. J Neural Transm 111: 69-89 (2004).
22. Grodstein F. Cardiovascular risk factors and cognitive function. Alzheimer Dement 3: S16-S22 (2007).
23. Panza F, Capurso C, D'Introno A, Colacicco AM, Frisardi V, Santamato A, et al. Vascular risk factors, alcohol intake, and cognitive decline. J Nutr Health Aging 12: 376-381 (2008).
24. Purnell C, Gao S, Callahan CM, Hendrie HC. Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord 23: 1-10 (2009).
25. Milionis HJ, Florentin M, Giannopoulos S. Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis? CNS Spectr 13: 606-613 (2008).
26. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Association of hyperli-pemia, diabetes mellitus and mild obesity. Acta Diabetol Lat 4: 572-590 (1967).
27. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553 (1998).
28. Reaven GM. Banting lecture 1988 Role of insulin resistance in human disease. Diabetes 37: 1595-1607 (1988).
29. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C; National Heart, Lung, and Blood Institute; American Heart Association. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24: 13-18 (2004).
30. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 285: 2486-2497 (2001).
31. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752 (2005).
32. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062 (2005).
33. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92: 399-404 (2007).
34. Maggi S, Noale M, Zambon A, Limongi F, Romanato G, Crepaldi G; ILSA Working Group. Validity of the ATP III diagnostic criteria for the metabolic syndrome in an elderly Italian Caucasian population: the Italian Longitudinal Study on Aging. Atherosclerosis 197: 877-882 (2008).
35. Haffner SM. The metabolic syndrome: inflammation, diabetes mel-litus, and cardiovascular disease. Am J Cardiol 97: 3A-11A (2006).
36. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 49: 403-414 (2007).
37. Kwon HM, Kim BJ, Lee SH, Choi SH, Oh BH, Yoon BW. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke 37: 466-472 (2006).
38. Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts incident stroke: a 14-year follow-up study in elderly people in Finland. Stroke 39: 1078-1083 (2008).
39. Peters R, Beckett N. Hypertension, dementia, and antihypertensive treatment: implications for the very elderly. Curr Hypertens Rep 11: 277-282 (2009).
40. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. JAMA 274: 1846-1851 (1995).
41. Elias MF, Wolf PA, D'Agostino RB, Cobb J, White LR. Untreated blood pressure level is inversely related to cognitive functioning: The Framingham study. Am J Epidemiol 138: 353-364 (1993).
42. Tzourio C, Dufouil C, Ducimetière P, Alpérovitch A. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 53: 1948-1952 (1999).
43. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment. A 20-year follow-up of 999 men. Hypertension 31: 780-786 (1998).
44. Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA. Hypertension and the risk of mild cognitive impairment. Arch Neurol 64: 1734-1740 (2007).
45. Panza F, Capurso C, D'Introno A, Colacicco AM, Santamato A, Capurso A, et al. Hypertension and mild cognitive impairment subtypes. Arch Neurol 65: 992-993 (2008).
46. de Carli C, Miller BL, Swan GE, Reed T, Wolf PA, Carmelli D. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 58: 643-647 (2001).
47. Tervo S, Kivipelto M, Hänninen T, Vanhanen M, Hallikainen M, Mannermaa A, et al. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cog-nitively healthy elderly subjects. Dement Geriatr Cogn Disord 17: 196-203 (2004).
48. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, et al; Italian Longitudinal Study on Aging Working Group. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 63: 1882-1891 (2004).
49. de bette S, Seshadri S. Vascular risk factors and dementia revisited. J Neurol Neurosurg Psychiatry 80: 1183-1184 (2009).
50. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21: 49-55 (2000).
51. Kivipelto M, Helkala E-L, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E e4 allele, elevated midlife total cholesterol level and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer's disease. Ann Intern Med 137: 149-155 (2000).
52. Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ 312: 805-808 (1996).
53. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4: 487-499 (2005).
54. Stewart R, Xue QL, Masaki K, Petrovitch H, Ross GW, White LR, et al. Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension 54: 233-240 (2009).
55. Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A, et al. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alz-heimers Dis 21: 691-724 (2010).
56. Birns J, Morris R, Donaldson N, Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens 24: 1907-1914 (2006).
57. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J Neurol Sci 229-230: 151-155 (2005).
58. McGuinness B, Todd S, Passmore P, Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev, CD004034 (2006).
59. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al.; HYVET Study Group. Treatment of hypertension in pa tients 80 years of age or older. N Engl J Med 358: 1887-1898 (2008).
60. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al.; HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG). a double-blind, placebo-controlled trial. Lancet Neurol 7: 683-689 (2008).
61. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63: 658-663 (2004).
62. Roriz-Filho JS, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, et al. (Pre)diabetes, brain aging, and cognition. Bio-chim Biophys Acta 1792: 432-443 (2009).
63. Yaffe K. Metabolic syndrome and cognitive disorders: is the sum greater than its parts? Alzheimer Dis Assoc Disord 21: 167-171 (2007).
64. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K. Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 164: 1327-1333 (2004).
65. Godstein F, Chen J, Wilson RS, Manson JE; Nurses' Health Study. Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care 24: 1060-1065 (2001).
66. Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Nara-yan KM, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 160: 174-180 (2000).
67. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 490: 169-175 (2004).
68. Vanhanen M, Koivisto K, Karjalainen L, Helkala EL, Laakso M, Soininen H, et al. Risk for non-insulin-dependent diabetes in the normoglycaemic elderly is associated with impaired cognitive function. NeuroReport 8: 1527-1530 (1997).
69. Fontbonne A, Berr C, Ducimetiere P, Alperovitch A. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care 24: 366-370 (2001).
70. Lindeman RD, Romero LJ, la Rue A, Yau CL, Schade DS, Koehler KM, Baumgartner RN, Garry PJ. A biethnic community survey of cognition in participants with type 2 diabetes, impaired glucose tolerance, and normal glucose tolerance: the New Mexico Elder Health Survey. Diabetes Care 24: 1567-1572 (2001).
71. Kumari M, Marmot M. Diabetes and cognitive function in a middle-aged cohort: findings from the Whitehall II study. Neurology 65: 1597-1603 (2005).
72. Scott RD, Kritz-Silverstein D, Barrett-Connor E, Wiederholt WC. The association of non-insulin-dependent diabetes mellitus and cognitive function in an older cohort. J Am Geriatr Soc 46: 1217-1222 (1998).
73. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 16: 693-704 (2009).
74. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154: 635-641 (2001).
75. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes melli-tus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14: 77-83 (2002).
76. Luchsinger JA, Reitz C, Patel B, Tang M-X, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol 64: 570-575 (2007).
77. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 65: 1066-1073 (2008).
78. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61: 661-666 (2004).
79. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 4: 363-381 (2008).
80. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 28: 726-735 (2005).
81. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63: 1187-1192 (2004).
82. Watson GS, Craft S. The role of insulin resistance in the patho-genesis of Alzheimer's disease: implications for treatment. CNS Drugs 17: 27-45 (2003).
83. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipo-protein E4 phenotype: cross-sectional population based study. BMJ 315: 1045-1049 (1997).
84. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Ma-saki KH, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 52: 971-975 (1999).
85. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53: 1937-1942 (1999).
86. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, et al. Risk of dementia among persons with diabetes mellitus: a population- based cohort study. Am J Epidemiol 145: 301-308 (1997).
87. Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51: 1256-1262 (2002).
88. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63: 1181-1186 (2004).
89. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56: 211-216 (2007).
90. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65: 545-551 (2005).
91. Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, et al. Diabetes mellitus in mid-life and the risk of dementia three decades later. Neurology 63: 1902-1907 (2004).
92. Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 10: 293-295 (2006).
93. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 27: 260-268 (2003).
94. Waldstein SR, Katzel LI. Interactive relations of central versus total obesity and blood pressure to cognitive function. Int J Obes (Lond) 30: 201-207 (2006).
95. Nourhashémi F, Deschamps V, Larrieu S, Letenneur L, Dartigues JF, Barberger-Gateau P; PAQUID study. Personnes Agées Quid. Body mass index and incidence of dementia: the PAQUID study. Neurology 60: 117-119 (2003).
96. Stewart R, Masaki K, Xue QL, Peila R, Petrovitch H, White LR, et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 62: 55-60 (2005).
97. White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease. J Am Geriatr Soc 44: 265-272 (1996).
98. Wang SY. Weight loss and metabolic changes in dementia. J Nutr Health Aging 6: 201-205 (2002).
99. Gustafson D. Adiposity indices and dementia. Lancet Neurol 5: 713-720 (2006).
100. Gorospe EC, Dave JK. The risk of dementia with increased body mass index. Age Ageing 36: 23-29(2007).
101. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Win-Blad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62: 1556-1560 (2005).
102. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330: 1360 (2005).
103. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163: 1524-1528 (2003).
104. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gun-Derson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 71: 1057-1064 (2008).
105. Atti AR, Palmer K, Volpato S, Winblad B, de Ronchi D, Fratigli-oni L. Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc 56: 111-116 (2008).
106. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology 65: 892-897 (2005).
107. Knopman DS, Edland SD, Cha RH, Petersen RC, Rocca WA. Incident dementia in women is preceded by weight loss by at least a decade. Neurology 69: 739-746 (2007).
108. Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R. Measures of adiposity and dementia risk in elderly persons. Arch Neurol 64: 392-398 (2007).
109. Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Long-streth WT, et al. Obesity: risk of dementia in the Cardiovascular Health Cognition Study. Arch Neurol 66: 336-342 (2009).
110. Panza F, D'Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, et al. Lipid metabolism in cognitive decline and dementia. Brain Res Rev 51: 275-292 (2006).
111. Atzmon G, Gabriely I, Greiner W, Davidson D, Schechter C, Barzilai N. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J Gerontol A Biol Sci Med Sci 57: M712-M715 (2002).
112. van Exel E, de Craen AJ, Gussekloo J, Houx P, Bootsma-van der Wiel A, MacFarlane P, et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol 51: 716-721 (2002).
113. van Vliet P, van de Water W, de Craen AJM, Westendorp RGJ. The influence of age on the association between cholesterol and cognitive function. Exp Gerontol 44: 112-122 (2009).
114. Henderson VW, Guthrie JR, Dennerstein L. Serum lipids and memory in a population based cohort of middle age women. J Neu-rol Neurosurg Psychiatry 74: 1530-1535 (2003).
115. Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 64: 1378-1383 (2005).
116. Reitz C, Tang MX, Manly J, Schupf N, Mayeux R, Luchsinger JA. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord 25: 232-237 (2008).
117. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59: 378-384 (2002).
118. Bonarek M, Barberger-Gateau P, Letenneur L, Deschamps V, Iron A, Dubroca B, et al. Relationships between cholesterol, apolipopro-tein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 19: 141-148 (2000).
119. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 57: 1447-1452 (2001).
120. Merched A, Xia Y, Visvikis S, Serot JM, Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 21: 27-30 (2000).
121. Wolf H, Hensel A, Arendt T, Kivipelto M, Winblad B, Gertz HJ. Serum lipids and hippocampal volume: the link to Alzheimer's disease? Ann Neurol 56: 745-748 (2004).
122. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 61: 705-714 (2004).
123. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 163: 1053-1057 (2003).
124. Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breitner JC, et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 65: 1045-1050 (2005).
125. Perlmuter LC, Nathan DM, Goldfinger SH, Russo PA, Yates J, Larkin M. Triglyceride levels affect cognitive function in noninsu-lin-dependent diabetics. J Diabet Complications 2: 210-213 (1988).
126. Sims R, Madhere S, Callender C, Campbell A. Patterns of relationships between cardiovascular disease risk factors and neuro-cognitive function in African Americans. Ethn Dis 18: 471-476 (2008).
127. de Frias CM, Bunce D, Wahlin A, Adolfsson R, Sleegers K, Cruts M, et al. Cholesterol and triglycerides moderate the effect of apolipoprotein E on memory functioning in older adults. J Gerontol B:Psychol Sci Soc Sci 62: 112-118 (2007).
128. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 20: 2255-2260 (2000).
129. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292: 2237-2242 (2004).
130. Dik MG, Jonker C, Comijs HC, Deeg DJ, Kok A, Yaffe K, et al. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 30: 2655-2660 (2007).
131. Yaffe K, Haan M, Blackwell T, Cherkasova E, Whitmer RA, West N. Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of Aging study. J Am Geriatr Soc 55: 758-762 (2007).
132. Komulainen P, Lakka TA, Kivipelto M, Hassinen M, Helkala EL, Haapala I, et al. Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women. Dement Geri-atr Cogn Disord 23: 29-34 (2007).
133. Ho RC, Niti M, Yap KB, Kua EH, Ng TP. Metabolic syndrome and cognitive decline in chinese older adults: results from the Singapore longitudinal ageing studies. Am J Geriatr Psychiatry 16: 519-522 (2008).
134. van den Berg E, Biessels GJ, de Craen AJ, Gussekloo J, Westen-dorp RG. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 69: 979-985 (2007).
135. Lee KS, Jang Y, Chung YK, Chung JH, Oh BH, Hong CH. Relationship between the diagnostic components of metabolic syndrome (MS) and cognition by ApoE genotype in the elderly. Arch Gerontol Geriatr 50: 69-72 (2009).
136. Roberts RO, Geda YE, Knopman DS, Cha RH, Boeve BF, Ivnik RJ, et al. Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study. Alzheimer Dis Assoc Disord 24: 11-18 (2009).
137. Yaffe K, Weston AL, Blackwell T, Krueger KA. The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol 66: 324-328 (2009).
138. Solfrizzi V, Scafato E, Capurso C, D'Introno A, Colacicco AM, Frisardi V, et al.; Italian Longitudinal Study on Aging Working Group Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging. Neurobiol Aging; doi:10.1016/j.neurobiolaging.2009.12.012 (2009).
139. Roriz-Cruz M, Rosset I, Wada T, Sakagami T, Ishine M, de Sá Roriz-Filho J, et al. Cognitive impairment and frontal-subcortical geriatric syndrome are associated with metabolic syndrome in a stroke-free population. Neurobiol Aging 28: 1723-1736 (2007).
140. Pugh KG, Lipsitz LA. The microvascular frontal-subcortical syndrome of aging. Neurobiol Aging 23: 421-431 (2002).
141. Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, Tzourio C, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 32: 169-174 (2009).
142. Solfrizzi V, Scafato E, Capurso C, D'Introno A, Colacicco AM, Frisardi V, et al.; Italian Longitudinal Study on Aging Working Group. Metabolic syndrome and the risk of vascular dementia. The Italian Longitudinal Study on Aging. J Neurol Neurosurg Psychiatry 81: 433-440 (2010).
143. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83: 735-743 (2006).
144. Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord 24: 185-192 (2007).
145. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, et al. Association of metabolic syndrome with Alzheimer disease: A population-based study. Neurology 67: 843-847 (2006).
146. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 64: 93-96 (2007).
147. Vilalta-Franch J, Lopez-Pousa S, Garre-Olmo J, Turón-Estrada A, Pericot-Nierga I. Metabolic syndrome in Alzheimer's disease: clinical and developmental influences. Rev Neurol 46: 13-17 (2008) [Spanish].
148. Neve RL, Robakis NK. Alzheimer's disease: a re-examination of the amyloid hypothesis. Trends Neurosci 21: 15-19 (1998).
149. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 64: 575-611 (2001).
150. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 21: 321-330 (2000).
151. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66: 300-305 (2009).
152. Bowler JV. Vascular cognitive impairment. J Neurol Neurosurg Psychiatry (Suppl 5): 35-44 (2005).
153. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev 1: 61-77 (2002).
154. Bokura H, Yamaguchi S, Iijima K, Nagai A, Oguro H. Metabolic syndrome is associated with silent ischemic brain lesions. Stroke 39: 1607-1609 (2008).
155. Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian Stroke Prevention Study. Ann Neurol 58: 610-616 (2005).
156. Park K, Yasuda N, Toyonaga S, Yamada SM, Nakabayashi H, Nakasato M, et al. Significant association between leukoaraiosis and metabolic syndrome in healthy subjects. Neurology 69: 974-978 (2007).
157. Furie KL, Smith EE. Metabolic syndrome: a target for preventing leukoaraiosis and age-related dementia? Neurology 69: 951-952 (2007).
158. Park K, Yasuda N, Toyonaga S, Tsubosaki E, Nakabayashi H, Shimizu K. Significant associations of metabolic syndrome and its components with silent lacunar infarction in middle aged subjects. J Neurol Neurosurg Psychiatry 79: 719-721 (2008).
159. Waldstein SR, Siegel EL, Lefkowitz D, Maier KJ, Brown JR, Obu-chowski AM, et al. Stress-induced blood pressure reactivity and silent cerebrovascular disease. Stroke 35: 1294-1298 (2004).
160. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Mark-esbery W, et al. Midlife blood pressure and neuritic plaques, neu-rofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol Aging 21: 57-62 (2000).
161. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab 7: 476-484 (2008).
162. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, et al. (2001) Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 22: 541-546.
163. Reaven G. Why a cluster is truly a cluster: insulin resistance and cardiovascular disease. Clin Chem 54: 785-787 (2008).
164. Cersosimo E, de Fronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Me-tab Res Rev 22: 423-436 (2006).
165. Craft S. Insulin resistance syndrome and Alzheimer disease: pa-thophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 20: 298-301 (2006).
166. Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? a systematic review. Eur J Pharmacol 585L: 97-108 (2008).
167. Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792: 482-496 (2009).
168. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apoli-poprotein E genotype. Neurology 50: 164-168 (1998).
169. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3: 169-178 (2004).
170. Small SA. The longitudinal axis of the hippocampal formation: its anatomy, circuitry, and role in cognitive function. Rev Neurosci 3: 183-194 (2002).
171. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitoge-nactivated protein kinase signaling. J Neurosci 21: 2561-2570 (2001).
172. Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJ. Degradation of amyloid betaprotein by a metalloprotease secreted by microglia and other neural and nonneural cells. J Biol Chem 272, 6641-6646 (1997).
173. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53: 474-481 (2004).
174. Mooradian AD. Central nervous system complications of diabetes mellitus-a perspective from the blood-brain barrier. Brain Res Brain Res Rev 23: 210-218 (1997).
175. Mankovsky BN, Metzger BE, Molitch ME, Biller J. Cerebrovascu-lar disorders in patients with diabetes mellitus. J Diabetes Complications 10: 228-242 (1996).
176. Li XL, Aou S, Oomura Y, Hori N, Fukunaga K, Hori T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 113: 607-615 (2002).
177. Harvey J. Leptin: a multifaceted hormone in the central nervous system. Mol Neurobiol 28: 245-258 (2003).
178. Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, te-Zapsidis N. Obesity-related leptin regulates Alzheimer's Abeta. FASEB J 18: 1870-1878 (2004).
179. Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord 24 (suppl 2): S80-S85 (2000).
180. Sapolsky RM. Glucocorticoids, stress, and their adverse neurological effects: relevance to aging. Exp Gerontol 34: 721-732 (1999).
181. Waldstein SR, Siegel EL, Lefkowitz D, Maier KJ, Brown JR, Obu-chowski AM, et al. Stress-induced blood pressure reactivity and silent cerebrovascular disease. Stroke 35: 1294-1298 (2004).
182. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61: 76-80 (2003).
183. Bravata DM, Wells CK, Concato J, Kernan WN, Brass LM, Gu-lanski BI. Two measures of insulin sensitivity provided similar information in a US population. J Clin Epidemiol 57: 1214-1217 (2004).
184. Axen KV, Dikeakos A, Sclafani A. High dietary fat promotes syndrome X in nonobese rats. J Nutr 133: 2244-2249 (2003).
185. Piers LS, Walker KZ, Stoney RM, Soares MJ, O'Dea K. The influence of the type of dietary fat on postprandial fat oxidation rates: monounsaturated (olive oil) vs saturated fat (cream). Int J Obes Re-lat Metab Disord 26: 814-821 (2002).
186. Vessby B, Unsitupa M, Hermansen K, Riccardi G, Rivellese AA, Tapsell LC, et al.; KANWU Study Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. Diabetologia 44: 312-319 (2001).
187. Lopez S, Bermudez B, Pacheco YM, Villar J, Abia R, Muriana FJ. Distinctive postprandial modulation of beta cell function and insulin sensitivity by dietary fats: monounsaturated compared with saturated fatty acids. Am J Clin Nutr 88: 638-644 (2008).
188. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J Neurosci Res 72: 141-146 (2003).
189. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, et al. CNS synatogenesis promoted by glia-derived cholesterol. Science 294: 1354-1357 (2001).
190. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endo-thelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15: 1987-1994 (1995).
191. Olesen OF, Dago L. High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils. Biochem Biophys Res Commun 270: 62-66 (2000).
192. Dantoine TF, Drouet M, Debord J, Merle L, Cogne M, Charmes JP. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann NY Acad Sci 977: 239-244 (2002).
193. Farr SA, Yamada KA, Butterfield DA, Abdul HM, Xu L, Miller NE, et al. Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology 149: 2628-2636 (2008).
194. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 38: 64-80 (2006).
195. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, et al. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 118: 2347-2364 (2008).
196. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, et al. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant Abeta in plasma. Neurobiol Dis 24: 114-127 (2006).
197. Sechi LA. Mechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity. J Hypertens 17: 1229-1237 (1999).
198. Mamo JC, Jian L, James AP, Flicker L, Esselmann H, Wiltfang J. Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment. Ann Clin Biochem 45: 395-403 (2008).
199. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334 (2001).
200. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50: 2384-2389 (2001).
201. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111, 1448-1454.
202. Grundy SM. (2003) Inflammation, hypertension, and the metabolic syndrome. JAMA 290: 3000-3002 (2005).
203. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107: 391-397 (2003).
204. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and metaanalysis of longitudinal studies. J Am Coll Cardiol 49: 403-414 (2007).
205. Inchiostro S, Fadini GP, de Kreutzenberg SV, Citroni N, Avogaro A. Is the metabolic syndrome a cardiovascular risk factor beyond its specific components? J Am Coll Cardiol 49: 2465 (2007).
206. Frisardi V, Solfrizzi V, Capurso C, Imbimbo BP, Vendemiale G, Seripa D, et al. Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? J Alzheimers Dis 21: 57-63 (2010).
207. Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancar-lo D, et al. Metabolic-Cognitive Syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 9: 399-417 (2010).
208. de Kosky ST. Statin therapy in the treatment of Alzheimer disease: what is the rationale? Am J Med 118 (Suppl 12A): 48-53 (2005).
209. DREAM (Diabetes REduction Assessment with ramipril and ro-siglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglita-zone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet 368: 1096-1105 (2006).
210. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13: 950-958 (2005).
211. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogeno-mics J 6: 246-254 (2006).
212. Gold M, Alderton C, Zvartau-Hind M, Ritche S, Saunders A, Craft S, et al. Effects of rosiglitazone as monotherapy in ApoE4-stratified subjects with mild-to-moderate Alzheimer's disease. Alz-heimers Dement 5 (Supplement 1): P86 (Abstract O1-04-06) (2009).